Abstract
Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis. Eligible subjects were adults with idiopathic pulmonary fibrosis of
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1622-1632 |
| Number of pages | 11 |
| Journal | European Respiratory Journal |
| Volume | 42 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 1 2013 |
Fingerprint
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
Macitentan for the treatment of idiopathic pulmonary fibrosis : The randomised controlled MUSIC trial. / Raghu, Ganesh; Million-Rousseau, Rachel; Morganti, Adele; Perchenet, Loïc; Behr, Juergen; Goh, N.; Glanville, A.; Musk, M.; Hopkins, P.; Lien, D. C.; Chan, C.; Rolf, J. D.; Wilcox, P.; Cox, P. G.; Manganas, H.; Cottin, V.; Valeyre, D.; Walleart, B.; Andreas, S.; Neurohr, C.; Guenther, A.; Schönfeld, N.; Koch, A.; Kramer, M.; Breuer, R.; Ben-Dov, I.; Fink, G.; Schwarz, Y.; Albera, C.; Confalonieri, M.; Saltini, C.; Harari, S.; Flezar, M.; Greenblatt, M.; Ras, G. J.; Morell, F.; Alvarez-Sala, J. L.; Xaubet, A.; Sueiro, A.; Linares, M. J.; Sköld, M.; Kayacan, O.; Mogulkoc, N.; Chan, Andrew; Chapman, J.; Parambil, J.; Ettinger, N.; Golden, J.; Meyer, K. C.; Swigris, J. J.; Yung, G. L.; Antin-Ozerkis, D.; Mohabir, P. K.; Wesselius, L. J.; De Andrade, J.; Cordova, F.; Safdar, Z.; Wencel, M.
In: European Respiratory Journal, Vol. 42, No. 6, 01.12.2013, p. 1622-1632.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Macitentan for the treatment of idiopathic pulmonary fibrosis
T2 - The randomised controlled MUSIC trial
AU - Raghu, Ganesh
AU - Million-Rousseau, Rachel
AU - Morganti, Adele
AU - Perchenet, Loïc
AU - Behr, Juergen
AU - Goh, N.
AU - Glanville, A.
AU - Musk, M.
AU - Hopkins, P.
AU - Lien, D. C.
AU - Chan, C.
AU - Rolf, J. D.
AU - Wilcox, P.
AU - Cox, P. G.
AU - Manganas, H.
AU - Cottin, V.
AU - Valeyre, D.
AU - Walleart, B.
AU - Andreas, S.
AU - Neurohr, C.
AU - Guenther, A.
AU - Schönfeld, N.
AU - Koch, A.
AU - Kramer, M.
AU - Breuer, R.
AU - Ben-Dov, I.
AU - Fink, G.
AU - Schwarz, Y.
AU - Albera, C.
AU - Confalonieri, M.
AU - Saltini, C.
AU - Harari, S.
AU - Flezar, M.
AU - Greenblatt, M.
AU - Ras, G. J.
AU - Morell, F.
AU - Alvarez-Sala, J. L.
AU - Xaubet, A.
AU - Sueiro, A.
AU - Linares, M. J.
AU - Sköld, M.
AU - Kayacan, O.
AU - Mogulkoc, N.
AU - Chan, Andrew
AU - Chapman, J.
AU - Parambil, J.
AU - Ettinger, N.
AU - Golden, J.
AU - Meyer, K. C.
AU - Swigris, J. J.
AU - Yung, G. L.
AU - Antin-Ozerkis, D.
AU - Mohabir, P. K.
AU - Wesselius, L. J.
AU - De Andrade, J.
AU - Cordova, F.
AU - Safdar, Z.
AU - Wencel, M.
PY - 2013/12/1
Y1 - 2013/12/1
N2 - Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis. Eligible subjects were adults with idiopathic pulmonary fibrosis of
AB - Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis. Eligible subjects were adults with idiopathic pulmonary fibrosis of
UR - http://www.scopus.com/inward/record.url?scp=84888166435&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888166435&partnerID=8YFLogxK
U2 - 10.1183/09031936.00104612
DO - 10.1183/09031936.00104612
M3 - Article
C2 - 23682110
AN - SCOPUS:84888166435
VL - 42
SP - 1622
EP - 1632
JO - European Respiratory Journal
JF - European Respiratory Journal
SN - 0903-1936
IS - 6
ER -